Rheumatoid Arthritis


Patient Perspective

Icon / Image / graphic


Research has come a long way, but RA is still a complex disease to treat

Up to 25% of RA patients in industrialised countries will not achieve low disease activity on biologic or synthetic DMARDs.1 While many patients will achieve ACR20, over 75% of MTX-IR or TNF-IR patients may not achieve low disease activity (i.e., ACR70) on targeted therapies.1

According to treat-to-target recommendations, the absence of remission or low disease activity requires a change in therapy.1 However, response to targeted therapies diminishes with every subsequent line of treatment.2

In RA, there is an increase in rates of serious infections, from less than 1/100 PYs in the healthy population to 5/100 PYs in people with RA.3 Patients with RA also have an increased risk of cardiovascular comorbidities and mortality compared with the general population.4-6


Looking for Product Information?

Register now to source clinical studies, expert insights and patient resources


Clinical Outcomes

Find out more about clinical outcomes.



Find out more about the unique role of JAKs in cytokine signalling.


ACR, American College of Rheumatology; DMARD, disease-modifying antirheumatic drug; HCP, healthcare provider; IR, intolerance or inadequate response; JAK, Janus kinase; PY, patient-year; RA, rheumatoid arthritis; STAT, signal transducer and activator of transcription; TNF tumour necrosis factor.


1. Aletaha D, Smolen JS. JAMA. 2018;320(13):1360-1372. 2. Rendas-Baum R, Wallenstein GV, Koncz T, et al. Arthritis Res Ther. 2011;13(1):R25. 3. Ravanbod H, Jazayeri J, Russell K, Carrroll G. J Immunol Infect Inflam Dis. 2017;2(3):1-9. 4. Crowson CS, Liao KP, Davis JM 3rd, et al. Am Heart J. 2013;166(4):622-628.e1. 5. Kaplan MJ. Rheum Dis Clin North Am. 2010;36(2):405-426. 6. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Arthritis Rheum. 2008;59(12):1690-1697.